I think it's a good announcement. I'm particularly encouraged...

I think it's a good announcement. I'm particularly encouraged about AML continuing, given its orphan drug status, and hopefully will see another readout later this year. Just disappointing to see the continued SP manipulation.

I'm also pleased about the business development side in the announcement - with "continuing to evaluate external opportunities that are complementary and strategically valuable". If I was having a guess, I reckon there's plans afoot for partnering and/or grant funding to continue the PTX-200 breast cancer and ovarian cancer trials.  And maybe another collaboration?

Separately - PTX-100 has been updated. it's still on track for a December readout. Also another test site has been added - the Peninsula & South Eastern Haematology and Oncology Group in Frankston.

https://clinicaltrials.gov/ct2/history/NCT03900442?A=3&B=6&C=Side-by-Side